An approach to the management of leukemia in the developing world

被引:6
作者
Chandy, M. [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Hematol, Vellore 63204, Tamil Nadu, India
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 2006年 / 28卷 / 03期
关键词
developing world; leukemia; management;
D O I
10.1111/j.1365-2257.2006.00777.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Management of leukemia is expensive. In the developing world where there are significant resource constraints, how does the physician manage leukemia? Government health budgets need to put their money into areas where a small investment is likely to benefit a large proportion of its people and these would include immunization, sanitation, family planning and treatment of communicable diseases and the cost of expensive treatments would have to be borne by the patient and family. However, in many of the emerging economies in the developing world, society is three-tiered in terms of resources with a small proportion being able to afford the best treatment, the middle class with the ability to meet a significant proportion of the healthcare costs on their own and the poor who depend wholly on what the Government health budget can afford. Providing an accurate diagnosis is possible even with limited resources and this must be made available to all. Sometimes a precise diagnosis even at the molecular level is more important in the developing world so that resources are not wasted on inappropriate treatments. Choosing a protocol for management based on resources available for the individual patient would appear ethically unacceptable, but is probably the only solution when wealth is unevenly distributed in society. This paper illustrates an approach to the management of leukemia in the developing world that has evolved with experience over two decades in a tertiary referral hospital in India.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 26 条
[1]   Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study [J].
Annino, L ;
Vegna, ML ;
Camera, A ;
Specchia, G ;
Visani, G ;
Fioritoni, G ;
Ferrara, F ;
Peta, A ;
Ciolli, S ;
Deplano, W ;
Fabbiano, F ;
Sica, S ;
Di Raimondo, F ;
Cascavilla, N ;
Tabilio, A ;
Leoni, P ;
Invernizzi, R ;
Baccarani, M ;
Rotoli, B ;
Amadori, S ;
Mandelli, F .
BLOOD, 2002, 99 (03) :863-871
[2]  
APPELBAUM FR, 2001, HEMATOLOGY AM SOC HE, V1, P62
[3]   Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered [J].
Byrd, JC ;
Dodge, RK ;
Carroll, A ;
Baer, MR ;
Edwards, C ;
Stamberg, J ;
Qumsiyeh, M ;
Moore, JO ;
Mayer, RJ ;
Davey, F ;
Schiffer, CA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3767-3775
[4]   Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461 [J].
Byrd, JC ;
Ruppert, AS ;
Mrózek, K ;
Carroll, AJ ;
Edwards, CG ;
Arthur, DC ;
Pettenatti, MJ ;
Stamberg, J ;
Koduru, PRK ;
Moore, JO ;
Mayer, RJ ;
Davey, FR ;
Larson, RA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1087-1094
[5]  
Chandy M, 2003, BLOOD, V102, p253B
[6]   Allogeneic bone marrow transplantation in the developing world: experience from a center in India [J].
Chandy, M ;
Srivastava, A ;
Dennison, D ;
Mathews, V ;
George, B .
BONE MARROW TRANSPLANTATION, 2001, 27 (08) :785-790
[7]   CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA IN INDIA - AN APPROACH TO MANAGEMENT IN A 3-TIER SOCIETY [J].
CHANDY, M .
MEDICAL AND PEDIATRIC ONCOLOGY, 1995, 25 (03) :197-203
[8]   High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia [J].
Douer, D ;
PrestonMartin, S ;
Chang, E ;
Nichols, PW ;
Watkins, KJ ;
Levine, AM .
BLOOD, 1996, 87 (01) :308-313
[9]   Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia [J].
Dworzak, MN ;
Fröschl, G ;
Printz, D ;
Mann, G ;
Pötschger, U ;
Mühlegger, N ;
Fritsch, G ;
Gadner, H .
BLOOD, 2002, 99 (06) :1952-1958
[10]   A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia [J].
Fenaux, P ;
Chastang, C ;
Chevret, S ;
Sanz, M ;
Dombret, H ;
Archimbaud, E ;
Fey, M ;
Rayon, C ;
Huguet, F ;
Sotto, JJ ;
Gardin, C ;
Makhoul, PC ;
Travade, P ;
Solary, E ;
Fegueux, N ;
Bordessoule, D ;
San Miguel, J ;
Link, H ;
Desablens, B ;
Stamatoullas, A ;
Deconinck, E ;
Maloisel, F ;
Castaigne, S ;
Preudhomme, C ;
Degos, L .
BLOOD, 1999, 94 (04) :1192-1200